Improving Care after Inherited Cancer Testing (IMPACT) Study

Miscellaneous

Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel

Multiple Cancer Types

Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination with Iberdomide (CC-220)/Dexamethasone versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study

Breast

Promoting Self-Management in Head and Neck Cancer Survivors with Lymphedema and Fibrosis [PROMISE Trial]

Head/Neck

A Phase 3, Randomized, Open-label, Multi-Center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-Muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy SunRISe-5

Bladder

Short Term Intensified Pembrolizumab (Keytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE

Kidney (Renal Cell)

Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel

Lymphoma

AssesSing a Biomarker PlatfOrm for STratifying IndeterminaTe Pulmonary Nodules; The SPOT IT Platform Trial

Lung

Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)

Kidney (Renal Cell)